Clinical Trial Listing

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit ClinicalTrials.gov.

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, hormone Receptor-Positive and HER2/neu Negative Breast Cancer (NCT 01674140)
Principal Investigator: Dr. Mary Cianfrocca

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (NCT02032823)
Principal Investigator: Dr. Shakeela Bahadur

A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment (NCT03056755)
Principal Investigator: Dr. Shakeela Bahadur

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) (NCT03330847)
Principal Investigator: Dr. Shakeela Bahadur

Effect of Preoperative Breast MRI on Surgical Outcomes, Cost and Quality of Life of Women with Breast Cancer (NCT01805076) 
Principal Investigator: Dr. Julie Billar 

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer (NCT03499353)
Principal Investigator: Dr. Lida Mina

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT01872975)
Principal Investigator: Dr. Emily Grade

Biliary Cancer

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda 

Colorectal Cancer

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) (NCT01349881)
Principal Investigator: Dr. Tomislav Dragovich 

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574)
Principal Investigator: Dr. Tomislav Dragovich   

Liver Cancer  

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma (NCT03289273)
Principal Investigator: Dr. Boris Naraev

Pancreatic Cancer 

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (NCT02923921)
Principal Investigator: Dr. Tomislav Dragovich

Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma (NCT03634332)
Principal Investigator: Dr. Tomislav Dragovich

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma (NCT03377491)
Principal Investigator: Dr. Tomislav Dragovich

Solid Tumor

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348
Principal Investigator: Dr. Jiaxin Niu

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors (NCT03179436) 
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC) (NCT03164772)
Principal Investigator: Dr. Jiaxin Niu

A Multicenter, Two-Part, Phase 2 Clinical Study of CMP-001 in Combination with atezolizumab with and without radiation therapy in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03438318)
Principal Investigator: Dr. Jiaxin Niu

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice(NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) (NCT03425643)
Principal Investigator: Dr. Qing Zhao

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer (NCT02716116)
Principal Investigator: Dr. Jiaxin Niu

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxin Niu

An Observational Registry Study to Evaluate the Performance of the BDX-XL2 Test (NCT03766958)
Principal Investigator: Dr. Archan Shah

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) (NCT01994382)
Principal Investigator: Dr. Javier Munoz

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies (NCT02343120)
Principal Investigator: Dr. Javier Munoz  

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466) 
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) (NCT03483103)
Principal Investigator: Dr. Javier Munoz (Please note: The study recruitment for this study are currently on hold)

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)
Principal Investigator: Dr. Javier Munoz

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma (NCT03677141)
Principal Investigator: Dr. Javier Munoz

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)(NCT03331198)
Principal Investigator: Dr. Javier Munoz

Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL (NCT01897571)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12) (NCT03761056)
Principal Investigator: Dr. Javier Munoz

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies (NCT03598608)
Principal Investigator: Dr. Javier Munoz

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT1872975)
Principal Investigator: Dr.Emily Grade

Bone Metastases

A randomized trial evaluating rapid delivery of dose escalated hypofractionated radiotherapy for patients diagnosed with bone metastases for effective palliation of
symptoms
 (NCT02163226)
Principal Investigator: Dr.Gary Walker 

Head and Neck Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer (NCT03689712)
Principal Investigator: Dr.Gary Walker

Prostate Cancer

Prospective Data Registry and Quality of Life Assessment of Men Undergoing High Dose Rate Brachytherapy of the Prostate Using Real-Time Ultrasound Planning 
Principal Investigator: Dr. Anna Likhacheva

Prospective Evaluation of Men Undergoing Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Principal Investigator: Dr. Rachit Kumar

Rectal Cancer

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Skin Cancer

Skin Surface Brachytherapy for Non-Melanoma Skin Cancers: Prospective Data Registry and Quality of Life Assessment
Principal Investigator: Dr.Emily Grade

Solid Tumor

EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial assessing the efficacy of upfront local consolidative therapy (LCT) for oligometastatic disease (NCT03599765)
Principal Investigator: Dr.Gary Walker

Schedule an Appointment

Call (480) 256-6444 or (855) 256-64444.

SELF REFER TO OUR CANCER CARE